{"nctId":"NCT00544882","briefTitle":"A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021","startDateStruct":{"date":"2007-10-31","type":"ACTUAL"},"conditions":["Healthy"],"count":61,"armGroups":[{"label":"DR-1021","type":"EXPERIMENTAL","interventionNames":["Drug: DR-1021","Drug: Kariva®"]},{"label":"Mircette","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mircette®","Drug: Kariva®"]}],"interventions":[{"name":"DR-1021","otherNames":["desogestrel/ethinyl estradiol"]},{"name":"Mircette®","otherNames":["desogestrel/ethinyl estradiol"]},{"name":"Kariva®","otherNames":["desogestrel/ethinyl estradiol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Premenopausal\n* Weight \\<200 lbs\n* Currently taking or willing to be treated with an oral contraceptive with a standard 21/7 regimen for one cycle prior to starting Study Cycle 1\n* Others as dictated by protocol\n\nExclusion Criteria:\n\n* Any contraindication to the use of oral contraceptives\n* Breast feeding\n* Smoking \\> 10 cigarettes per day\n* Use of drugs that require simultaneous use of contraceptives (e.g., isotretinoin \\[Accutane\\])\n* Others as dictated by protocol","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Serum Estradiol Levels by Cycle Day","description":"Levels of estradiol were measured throughout the study from blood samples.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.00","spread":null},{"groupId":"OG001","value":"51.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.50","spread":null},{"groupId":"OG001","value":"34.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.00","spread":null},{"groupId":"OG001","value":"29.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.00","spread":null},{"groupId":"OG001","value":"20.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.00","spread":null},{"groupId":"OG001","value":"19.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":null},{"groupId":"OG001","value":"26.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.00","spread":null},{"groupId":"OG001","value":"26.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.00","spread":null},{"groupId":"OG001","value":"20.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.00","spread":null},{"groupId":"OG001","value":"27.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.00","spread":null},{"groupId":"OG001","value":"43.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.00","spread":null},{"groupId":"OG001","value":"27.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.50","spread":null},{"groupId":"OG001","value":"32.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Follicles Greater Than 5 mm in Diameter","description":"Ovarian follicles were measured by trans-vaginal ultrasound. The size of the 3 largest follicles was documented for each participant, and the percentage of follicles greater than 5 mm in diameter was calculated based on the total number follicles present (indicated by n for each time point).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"29.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"27.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"26.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"31.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"35.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"31.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"31.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"18.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":null},{"groupId":"OG001","value":"24.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":null},{"groupId":"OG001","value":"27.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day","description":"Levels of follicle stimulating hormone were measured throughout the study from blood samples.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","spread":null},{"groupId":"OG001","value":"4.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.55","spread":null},{"groupId":"OG001","value":"3.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":null},{"groupId":"OG001","value":"3.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":null},{"groupId":"OG001","value":"1.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":null},{"groupId":"OG001","value":"2.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":null},{"groupId":"OG001","value":"3.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":null},{"groupId":"OG001","value":"3.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":null},{"groupId":"OG001","value":"3.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.05","spread":null},{"groupId":"OG001","value":"4.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.90","spread":null},{"groupId":"OG001","value":"4.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":null},{"groupId":"OG001","value":"3.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.50","spread":null},{"groupId":"OG001","value":"2.50","spread":null}]}]}]},{"type":"PRIMARY","title":"Serum Inhibin-B Levels by Cycle Day","description":"Levels of inhibin-B were measured throughout the study from blood samples.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.30","spread":null},{"groupId":"OG001","value":"99.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.80","spread":null},{"groupId":"OG001","value":"64.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.35","spread":null},{"groupId":"OG001","value":"41.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.15","spread":null},{"groupId":"OG001","value":"28.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.10","spread":null},{"groupId":"OG001","value":"32.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.80","spread":null},{"groupId":"OG001","value":"55.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.20","spread":null},{"groupId":"OG001","value":"62.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.60","spread":null},{"groupId":"OG001","value":"49.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.95","spread":null},{"groupId":"OG001","value":"55.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.70","spread":null},{"groupId":"OG001","value":"57.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.10","spread":null},{"groupId":"OG001","value":"52.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.15","spread":null},{"groupId":"OG001","value":"29.55","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Cycle 2 Days 1 - 20 to Cycle 2 Days 21 - 28 in Maximum Follicle Size","description":"The change in the size of the largest documented follicle during combination therapy (Days 1 to 21) and during monotherapy/placebo (Days 21-28) measured by trans-vaginal ultrasound.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.02","spread":"6.076"},{"groupId":"OG001","value":"-1.79","spread":"3.081"}]}]}]},{"type":"SECONDARY","title":"Number of Days of Bleeding or Spotting During Unscheduled and Scheduled Study Periods","description":"The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal \\[Day 22 to Day 28 of each cycle\\]) bleeding or spotting was derived from participant diaries.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":"3.732"},{"groupId":"OG001","value":"1.41","spread":"1.551"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.19","spread":"2.167"},{"groupId":"OG001","value":"3.67","spread":"1.754"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":"2.808"},{"groupId":"OG001","value":"1.64","spread":"2.614"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Bleeding or Spotting During Unscheduled and Scheduled Study Periods","description":"The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal \\[Day 22 to Day 28 of each cycle\\]) bleeding or spotting was derived from participant diaries.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"59.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"92.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"53.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Bleeding During Unscheduled and Scheduled Study Periods","description":"The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal \\[Day 22 to Day 28 of each cycle\\]) bleeding (not including spotting) was derived from participant diaries.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"2.127"},{"groupId":"OG001","value":"0.52","spread":"0.935"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":"1.793"},{"groupId":"OG001","value":"2.63","spread":"1.843"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"1.436"},{"groupId":"OG001","value":"0.71","spread":"1.607"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Bleeding During Unscheduled and Scheduled Study Periods","description":"The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal \\[Day 22 to Day 28 of each cycle\\]) bleeding (not including spotting) was derived from participant diaries.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":28},"commonTop":["Upper respiratory tract infection","Nasal congestion","Nasopharyngitis","Urinary tract infection","Back pain"]}}}